Evaxion Biotech, a Danish Phase 1/2 biotech using AI to develop immuno-oncology therapies, filed on Friday with the SEC to raise up to $35 million in an initial public offering.
The company is using the AI technology of its PIONEER and EDEN platforms to develop four product candidates. Its lead candidates are EVX-01, for the treatment of metastatic and unresectable melanoma, non-small cell lung cancer, and bladder cancer; and EVX-02, for the adjuvant treatment of melanoma. EVX-01 and EVX-02 are both currently in Phase 1/2a trials, with data expected in the 1H21.
The Copenhagen, Denmark-based company was founded in 2008 and plans to list on the Nasdaq under the symbol EVAX. Evaxion Biotech filed confidentially on October 22, 2020. Oppenheimer & Co. and Ladenburg Thalmann are the joint bookrunners on the deal. No pricing terms were disclosed.
